FLT4 and wet macular degeneration: A soluble form of VEGFR3 that blocks the interaction of VEGFC and VEGFD with VEGFR2 and VEGFR3 is currently in clinical trial for wet age-related macular degeneration and diabetic macular oedema, both of which are characterised by the development of tortuous and leaky blood vessels in the eye [108].